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Abstract
The MST1R (RON) kinase is overexpressed in >80% of human pancreatic cancers, but its role in 
pancreatic carcinogenesis is unknown. In this study, we examined the relevance of Mst1r kinase to 
Kras driven pancreatic carcinogenesis using genetically engineered mouse models. In the setting 
of mutant Kras, Mst1r overexpression increased acinar-ductal metaplasia (ADM), accelerated 
progression of pancreatic intraepithelial neoplasia (PanIN), and resulted in the accumulation of 
(mannose receptor C type 1) MRC1+, (arginase 1) Arg+ macrophages in the tumor 
microenvironment. Conversely, absence of a functional Mst1r kinase slowed PanIN initiation, 
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resulted in smaller tumors, prolonged survival and a reduced tumor associated macrophage 
content. Mst1r expression was associated with increased production of its ligand Mst1, and in 
orthotopic models, suppression of Mst1 expression resulted in reduced tumor size, changes in 
macrophage polarization and enhanced T cell infiltration. This study demonstrates the functional 
significance of Mst1r during pancreatic cancer initiation and progression. Further, it provides 
proof of concept that targeting Mst1r can modulate pancreatic cancer growth and the 
microenvironment. This study provides further rationale for targeting Mst1r as a therapeutic 
strategy.
Keywords
Mst1r; MST1R; MST1; pancreatic cancer; macrophage
INTRODUCTION
Over the last several years, the genetic alterations that govern pancreatic carcinogenesis have 
been well-characterized and multiple genetically engineered mouse models of pancreatic 
cancer have been developed based on known driver mutations1–4. Disappointingly, however, 
our ability to translate these discoveries into impactful therapies remains slow and yet 
overall, less emphasis has been placed on downstream changes in gene and protein 
expression, often because these changes are dynamic, ill-defined, and therefore of unclear 
significance.
The upregulation of MST1R tyrosine kinase expression is a molecular event of particular 
interest in many epithelial neoplasms, as it can mediate oncogenic phenotypes and addiction 
to KRAS signaling5,6. Additionally, MST1R signaling has been shown to promote 
alternative activation of macrophages, which are potently immunosuppressive. Thus, 
MST1R on tumor cells and in tumor-associated macrophages is potentially targetable7. 
However, it remains unclear whether MST1R signaling actually promotes pancreatic cancer 
progression or if MST1R overexpression merely represents an epiphenomenon.
To address this question, we utilized mouse genetic gain and loss of function approaches. 
For Mst1r overexpression, we created a transgenic mouse strain to express Mst1r, in a 
pancreas specific manner while we used a Mst1r knock-in strain containing a targeted 
deletion of the tyrosine kinase signaling domain to study loss of Mst1r function. These 
studies reveal that in the setting of oncogenic Kras, Mst1r accelerates pancreatic duct 
neoplasia and progression to adenocarcinoma, though it is not absolutely required, and that 
functional Mst1r kinase results in increased tumor macrophage content and changes in 
polarization. Mst1r expression was associated with increased expression of its cognate 
ligand, Mst1. Additional studies in an orthotopic model demonstrate that loss of Mst1 
expression, also resulted in reduced tumor growth associated with macrophage polarization 
toward the M1 state, suggesting that targeting Mst1/Mst1r signaling warrants continued 
investigation.
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RESULTS
Mst1r Expression Accelerates Pancreatic Carcinogenesis
To study the effects of Mst1r expression on pancreatic duct carcinogenesis, we developed a 
transgenic mouse to direct pancreas-specific expression of the wild-type Mst1r protein using 
a Mst1r murine minigene driven by the Pdx-1 promoter utilized in our Pdx-1-cre strain 
(Pdx-1-Mst1r) (Supplemental 1A)4. Founder Pdx-1-Mst1r mice demonstrated 2-fold greater 
expression of Mst1r protein compared to normal pancreas (Supplemental 1B). A cohort of 
32 Pdx-1-Mst1r mice were aged to 18 months. Fourteen animals were sacrificed at 
approximately 10 months secondary to severe dermatitis. Pdx-1 is expressed in terminally 
differentiated keratinocytes in the spinous layer of the epidermis, suggesting that Mst1r 
overexpression in the skin of these animals resulted in dysregulated inflammation11. No 
overt histopathologic changes were evident in the pancreata of these animals. Remaining 
mice were sacrificed at 18 months of age. While no overt pancreatic neoplasia developed in 
17 mice, 1 animal developed a moderately-poorly differentiated primary pancreatic ductal 
adenocarcinoma with liver metastases (Supplemental 1C–I). Immunofluorescent staining for 
the epithelial marker CK-19 demonstrated ductal structures in both the primary pancreatic 
tumor and liver metastases (Supplemental 1H–I).
Since the majority of human pancreatic cancers harbor mutant Kras, we were most 
interested in studying the effects of Mst1r signaling in this setting. Thus, Pdx-1-Mst1r mice 
were bred to LSL-KrasG12D mice to yield mice (KR), which were then bred with Pdx-1-Cre 
to yield the compound strain termed, KRC, that overexpressed Mst1r in the pancreas in the 
presence of mutant Kras.
Animals were sacrificed at times ranging from 6 weeks to 15 months along with aged-
matched controls (KC). Pancreatic tissue sections were analyzed for histology and 
immunostained to characterize Mst1r expression. Both KC and KRC strains exhibited 
acinar-ductal metaplasia (ADM) and PanIN formation (Figure 1A, B), though ADM was 
considerably more prominent in KRC mice (Figure 1C). In wild-type mice, basal Mst1r 
expression was restricted to islets (Supplemental 2A). In contrast, both KC and KRC strains 
demonstrated areas of Mst1r expression in ADM and PanIN lesions (Supplemental 2B), 
which were not present in wild-type pancreata. The presence of Mst1r expression in KC 
animals is likely secondary to known upregulation of Mst1r downstream of mutant KRAS12. 
In KRC mice, we observed an additional pattern of Mst1r expression, particularly in large 
lesions with extensive ADM. These areas of Mst1r expression were marked by concomitant 
expression of nuclear Pdx-1 consistent with presence of the Mst1r transgene (Figure 1D).
We next compared age-matched KC, and KRC pancreata to determine the consequences 
gain of Mst1r function. Lesions that developed in KC mice up to 3 months were 
predominantly low grade PanIN (Figure 1E). In contrast, by 3 months, KRC mice developed 
large, abundant foci of ADM, many of which appeared to progress directly to high grade 
PanIN, a phenomenon we rarely observed in KC pancreata (Figure 1E). These lesions 
demonstrated a 2-fold increase in proliferation as assayed by Ki67 qPCR (Supplemental 
2C). At later time points (6–9 months), KRC pancreata consistently contained more 
advanced PanIN than KC controls (Supplemental 2D, n=6, p <0.05). In fact, 9 month KRC 
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pancreata were nearly replaced with high grade PanIN and invasive cancer, while lesions in 
KC pancreata remained predominantly low grade (Figure 1E). The survival of KRC mice 
was markedly reduced as compared to KC animals, in which median survival was not 
reached (Figure 1F, 95% CI 43–51 weeks). While we did observe liver and lung metastases 
in KRC mice as early as 3 months, it appeared that local disease progression was the most 
common cause of early lethality. Taken together, these results demonstrate that Mst1r 
accelerates both the initiation and progression of Kras-mediated pancreatic duct neoplasia in 
the mouse.
Loss of Functional Mst1R Kinase Slows Progression to Pancreatic Cancer
After finding that Mst1R kinase overexpression results in acceleration of pancreatic duct 
neoplasia, we sought to determine if Mst1r was required for progression to pancreatic 
cancer. Loss of function studies were conducted using mice with a targeted deletion of the 
tyrosine kinase signaling domain of the receptor, Mst1r TK−/− (referred to as TK−/−), created 
via a knock-in-out strategy8. Note that while, gain of function studies were conducted on a 
129/B6 hybrid background, loss of function studies were conducted on a pure C57/B6 
background with paired littermates. TK−/− mice were bred to LSL-KRASG12D and Pdx-1-
Cre mice ultimately, yielding KTK−/−C, a strain bearing pancreas specific expression of 
mutant Kras with a functionally inactive Mst1r kinase. In stark contrast to KC mice, PanIN 
initiation and progression was delayed in KTK−/−C mice In these mice, sparse PanIN were 
apparent at 3 months of age, and those that were present were low grade (Figure 1E). In 
KTK−/−C mice, PanIN began to appear regularly at approximately 6 months, were 
predominantly low grade and these persisted well beyond 12 months with delayed 
progression to invasive cancer (Figure 1E). The survival of KTK−/−C mice significantly 
exceeded that of KC littermate controls (p=0.02) (Figure 1G). While we did observe 
eventual progression to carcinoma in some animals, total pancreas weight in KTK−/−C was 
reduced by 40% (Supplemental 2E) and tumor formation in KTK−/−C was much more focal 
as compared to KC in which multiple areas of the pancreas were involved by invasive 
carcinoma (Supplemental 2F). Thus, Mst1r function is not required for, but does 
significantly accelerate progression to pancreatic cancer.
Mst1r Signaling Alters Macrophage Polarization
In normal biology, Mst1r signaling results in attenuation of inflammation, by promoting 
changes in macrophage polarization from an “M1” and toward an “M2” state, as 
characterized by increased expression of M2 cell surface markers such as CD163 and 
MRC113,14. During our examinations of pancreatic histology from the gain and loss of 
function Mst1r strains, we noted clear differences in the immune cell infiltrates. We 
therefore characterized the number of F4/80+ macrophages and found a marked increase in 
KRC pancreata compared with KC at 6 months of age (Figure 2A). In comparing KC to 
KTK−/−C mice, the difference in macrophage accumulation was apparent even earlier, as 
macrophages are almost completely absent from KTK−/−C pancreata until 3m of age (Figure 
2B). To more rigorously assess macrophage content, we examined macrophage content in 
the three strains using immunofluorescent double-labelling with F4/80+ and CD68+. This 
study confirmed the quantity of double labelled cells correlated with increasing expression 
of functional Mst1r kinase using strain-specific background controls (Supplemental 3A). We 
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next examined the relative abundance of CD68+/CD163+ macrophages over time in the KC, 
KRC and KTK−/−C strains and noted that double-labelled cells were most abundant in KRC 
and least abundant in KTK−/−C pancreata, consistent with the relative activity of Mst1r 
kinase (Figure 2C–D and Supplemental Figure B).
To further characterize the macrophage content, we examined pancreatic and splenic tissues 
from KC and KRC mice using multi-color flow cytometry15. We observed comparable 
infiltrates of CD45+CD11b+Gr1lo myeloid-lineage cells in KRC and KC animals, in both 
pancreatic and splenic cell suspensions (Figure 2E). After identifying the fraction of 
CD45+CD11b+Gr-1lo infiltrating cells, we then further characterized their expression of 
CD11c, a marker of inflammatory macrophages, and MRC1, another marker of 
immunosuppressive, tumor-associated macrophages16,17. Similar to our IHC studies, we 
observed the fraction of macrophages expressing cell surface markers indicative of an 
immunosuppressive phenotype (MRC1+) were significantly greater in KRC than in KC 
pancreata, while the fraction of CD11c+ macrophages was significantly greater in KC than 
in KRC pancreata (Figure 2F). Given our prior observations that KC pancreata develop 
increasing Mst1r expression associated with PanIN progression, we determined the relative 
quantity of Mst1r expression by Q-RT-PCR in order to characterize the relationship of 
macrophage phenotype to Mst1r expression. This analysis revealed that, independent of 
strain, high Mst1r expression was associated with a significant increase in the percentage of 
double positive MRC1+/CD11c+ macrophages as compared with tissues that had low Mst1r 
expression (p=0.01) (Figure 2G).
To further characterize macrophage phenotypes, we performed immunofluorescent staining 
of KRC pancreatic tissues using the markers F4/80, MRC1, MHC II, and Arginase I. 
Staining revealed that F4/80+/MRC1+ macrophages had a distinct morphology. These cells 
were small, round, and were frequently embedded in dense fibrous stroma surrounding the 
neoplastic cells (Supplemental Figure 4A). Additionally, these cells expressed Arginase I, a 
functional marker of the immunosuppressive tumor-promoting macrophages (Supplemental 
Figure 4B)18. We then stained these tissues for expression of MHCII, a marker of 
inflammatory macrophages with antigen presentation capacity17. In contrast to MRC1+ 
macrophages, MHCII+ cells were much larger with vacuolated cytoplasm suggestive of 
phagocytic activity and antigen-presenting capability (Supplemental Figure 4C). Multiple 
areas of F4/80+ cells were identified primarily in KRC pancreata, a result consistent with 
our flow cytometry data that demonstrated an increased number of double positive MRC1+/
CD11c+ macrophages in tissues with high levels of Mst1r expression. Additionally, many of 
these macrophages co-stained with Ki67, a marker of active replication (Supplemental 
Figure 4D).
KPC mice have been shown to develop splenomegaly secondary to extramedullary 
hematopoiesis and accumulation of splenic CD11b+Gr1lo myeloid-derived suppressor 
cells18,19. We next analyzed the spleens of KRC and KC animals and observed a similar 
pattern of CD11b+Gr1lo expression. However, we did not observe any accumulation of 
either CD11c+ or MRC1+ macrophages in the spleen of KRC or KC animals, strongly 
suggesting that the differentiation of these macrophages is a result of soluble factors present 
within the tumor microenvironment (Supplemental Figure 4E).
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Mst1-Mst1r Signaling Attenuates the M1 Macrophage State, But Does Not Independently 
Drive M2 Differentiation In Vitro
To further investigate if the alterations in macrophage phenotype observed were due to 
Mst1r signaling, we next examined if ligand-induced Mst1r activation was capable of 
altering macrophage polarization in vitro. Bone marrow-derived macrophages were treated 
with either Mst1r ligand, Mst1, or tumor conditioned media from a murine pancreatic cancer 
cell line, LMP, that expresses Mst1r20. Macrophages were treated with either IL-4 to 
polarize toward the immunosuppressive “M2” state (measured by expression of TGF-β and 
Arginase-1) or IFN-γ LPS to induce an inflammatory “M1” state (measured by expression 
of IFN-γ, IL-12β, and inducible nitric oxide synthase (iNOS)21. Mst1 stimulation inhibited 
the expression of IFN-γ IL-12 and iNOS but did not induce expression of Arginase I or 
TGF-β (Figure 3A, B). Thus, in this experimental setting, exposure to Mst1 strongly 
attenuated inflammatory M1 polarization, but did not fully induce an immunosuppressive 
M2 phenotype. LMP conditioned media, however, was capable of inducing M2 
differentiation (Figure 3B), suggesting that signals in addition to Mst1r activation are 
required to fully drive polarization toward the M2 phenotype.
Mst1r Activates an Autocrine/Paracrine Positive Feedback Loop
We next sought to determine how Mst1r signaling in the epithelial tumor cell was effecting 
changes in macrophage state in the pancreatic tumor microenvironment. Given the effects of 
Mst1 on macrophage polarization, we hypothesized that Mst1r overexpression may in fact 
result in upregulation of Mst1 expression and secretion. To explore this, we derived multiple 
epithelial cell lines from tumors arising in KC and KRC pancreata and characterized their 
Mst1r and Mst1 expression by Q-RT-PCR. These studies revealed that Mst1r expressing 
lines demonstrated 10- to 60-fold increases in Mst1 expression as compared to Mst1r 
negative lines (Figure 4A). Additionally, we used a luciferase reporter assay to interrogate 
whether the Mst1r promoter was activated in response to Mst1 stimulation in multiple 
murine pancreatic cancer cell lines (PanIN 4313 and LMP). We found a significant increase 
in Mst1r transcription when stimulated with Mst1, with a positive regulatory response 
element located between −335 and −485 bp within the Mst1r promoter (Figure 4B, C). We 
similarly observed an increase in Mst1r transcript after bone marrow derived macrophages 
were exposed to Mst1 (Figure 4D). Immunostaining for Mst1 in pancreatic tissues 
confirmed Mst1 expression in epithelial cells with increased frequency/intensity in KRC vs. 
age-matched KC mice (Figure 4E). Finally, we screened tissue lysates for Mst1 protein 
levels and found significantly higher levels of Mst1 during disease progression 
(Supplemental 5A,B). Together, these data suggest that increased Mst1r expression results in 
increased expression of Mst1 by both pancreatic cancer cells and macrophages.
Mst1/Mst1r Knockdown Significantly Inhibits Tumor Growth In Vivo
To further test the hypothesis that Mst1r signaling from the epithelial tumor cell influences 
the tumor microenvironment, we utilized lentiviral shRNA to achieve knockdown of Mst1 
expression in murine LMP cells (Figure 5A). The LMP pancreatic cancer cell line, derived 
from liver metastases of KPC mice, is highly tumorigenic when xenografted into the 
pancreata of syngeneic B6/129 F1 hybrid mice20. While Mst1 deficient cells were able to 
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proliferate in vitro, they did proliferate more slowly than Mst1 intact cells (Supplemental 
5C). Both lines were able to form tumors after orthotopic injection, however there was a 
profound reduction in tumor size from Mst1 deficient versus Mst1 intact lines (Figure 5B). 
We next performed flow cytometry on these tumors to determine the ratio of F4/80+/CD11c
+ to F4/80+/MRC1+ expressing macrophages. Notably, the number of MRC1+ macrophages 
was markedly reduced in Mst1 deficient LMP tumors (p=0.03), suggesting that Mst1 
secreted into the tumor microenvironment modulates macrophage polarization (Figure 5C). 
In orthotopic tumors, immunostaining for CD3+ T cells revealed marked infiltration 
throughout Mst1 deficient tumors, as compared to controls in which T cells were observed 
nearly exclusively at the periphery (Figure 5D). When we repeated this experiment in 
immunodeficient NSG mice, Mst-1 deficient tumors grew faster causing earlier lethality 
(data not shown), suggesting that an adaptive immune response was at least in part, 
responsible for growth suppression in the absence of Mst1-Mst1r signaling. Together, with 
our prior findings, these results suggest that Mst1r expression by pancreatic cancer cells 
results in secreted Mst1 protein that is then available to initiate autocrine and paracrine 
signaling within the tumor microenvironment (Figure 6A).
Mst1r Expression Correlates with Increased Ccl2 Secretion by Pancreatic Cancer Cells
Finally, we took advantage of the LMP Mst1/Mst1r knockdown cell lines to try and identify 
chemokines which may mediate the Mst1r related accumulation of macrophages in the 
pancreatic tumor microenvironment. We performed an ELISA to measure cytokine/
chemokine levels on conditioned media from LMP control and knockdown cells. This 
revealed that an 8 fold reduction in the level of Ccl2 in the absence of Mst1/Mst1r 
expression (Figure 5E). To further evaluate this finding, we assayed for mRNA levels of 
Ccl2 in 3 month old pancreata from KRC and KTK−/−C mice. This confirmed a greater than 
2 fold reduction in Ccl2 mRNA in KTK−/−C versus KRC mice (Figure 5F). As Ccl2 has 
been shown to mediate localization of bone marrow derived monocytes to the pancreatic 
tumor microenvironment, these findings suggest Mst1r mediated secretion of Ccl2 is at least 
partially responsible for our observations that macrophage content correlated with the level 
of functional Mst1r signaling22,23.
MST1R Expression Is Associated With Poor Outcomes in Human Pancreatic Cancer
To determine whether our findings regarding the relevance of Mst1r signaling in the mouse 
were relevant to human disease, we examined gene expression data from two independent 
cohorts. We first analyzed a publicly available dataset containing a gene expression profiling 
of 125 human primary pancreatic cancers and 46 normal pancreas (GSE71729). We 
confirmed MST1R overexpression in cancers compared with normal pancreas (data not 
shown). Interestingly we found that patients with a high expression of MST1R had a 
significantly worse overall survival (p = 0.0285). Analysis of the TCGA’s pancreatic cancer 
cohort confirmed the association between high MST1R expression and poor overall survival 
(p = 0.0009) and also revealed that high expression of MST1R was associated with poorer 
disease-free survival (p < 0.0001) (Figures 6B,C).
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DISCUSSION
The MST1R kinase is overexpressed in human pancreatic cancer yet its contribution to 
pancreatic carcinogenesis remains unknown. In this study, we examined the consequences of 
gain and loss of Mst1r function in genetically engineered mouse models of pancreatic 
carcinogenesis initiated by mutant KRAS, widely accepted as a relevant model of human 
disease. Mst1r gain and loss of function each modulated pancreatic carcinogenesis, resulting 
in significant changes in survival. Mst1r associated carcinogenesis was marked by: 1) earlier 
onset of ADM that appears to progress rapidly to high-grade PanIN, 2) More rapid 
progression to invasive cancer, and 3) modulation of the immune microenvironment toward a 
tumor permissive phenotype.
Given the predominantly embryologic expression of the Pdx-1 promoter, the initial degree of 
Mst1r overexpression in the KRC compound strain is modest. As expected, we identified a 
progressive increase in Mst1r expression in KC mice, consistent with its putative role as a 
Kras effector6. The increasing expression of Mst1r in Kras mutant mice is important to 
highlight because they bias the experimental results towards the null hypothesis, when 
comparing KRC to KC mice, making the differences we observed more noteworthy. It is 
clear from our studies, however, that while Mst1r promotes disease progression in the setting 
of oncogenic Kras, it is not absolutely required for pancreatic carcinogenesis. In loss of 
function studies, we observed an obvious delay in disease progression and a modest, though 
statistically significant improvement in survival. Concordant with these findings, we 
observed a smaller tumor burden in the absence of Mst1r kinase activity. Importantly, 
mining of two independent databases revealed that high levels of Mst1r expression are a 
poor prognostic factor for survival in pancreatic cancer patients. These findings are in 
contrast to a prior report that failed to find MST1R prognostic for survival24. This disparity 
may be at least partially explained by some differences in methodology between the studies. 
The prior study initially characterized MST1R expression by immunohistochemistry using 
an antibody that we have found to bind off-target antigens. The IGCC mRNA data from this 
study, as the authors acknowledged, also had short follow-up at the time of their analysis.
Studies in other tumor types have similarly found that MST1R signaling impacts tumor 
progression9,25–27. One purported mechanism by which MST1R impacts tumor progression 
is via its expression on macrophages within the tumor microenvironment. MST1R signaling 
in peritoneal macrophages has been shown to drive macrophages away from immune-
surveillance (the so-called “M1” state) towards an alternative, tumor-promoting “M2” 
phenotype via a mechanism that involves attenuation of iNOS and increased expression of 
Arginase-17,8,13,14. We therefore hypothesized that in addition to its effects on the epithelial 
tumor cell, MST1R signaling may affect pancreatic carcinogenesis indirectly by altering the 
polarization of infiltrating myeloid cells and/or tissue resident macrophages in the tumor 
microenvironment towards a tumor-promoting, immunosuppressive phenotype.
In keeping with this, we show that Mst1r overexpression in murine epithelial tumor cells is 
associated with upregulation of its own ligand, Mst1. These results are consistent with recent 
studies documenting tumor cell specific MST1 upregulation in both mouse and human 
prostate cancer28,29. We further found that Mst1 induces activation of the Mst1r promoter. 
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To our knowledge, this reciprocal signaling between Mst1r expression and its own ligand, 
Mst1, has not been described. This finding that Mst1r signaling enhances Mst1 expression 
and that conversely, Mst1 knockdown is associated with decreased Mst1r expression, 
demonstrates the presence of a feed forward signaling loop leading both to an autocrine 
effect on Mst1r-expressing tumor cells, as well as a paracrine effect on Mst1r expressing 
macrophages within the tumor microenvironment. In the macrophage, Mst1-Mst1r signaling 
attenuates the expression of genes associated with tumor surveillance7. Since we observed 
that Mst1 stimulation is capable of attenuating the M1 phenotype, but not inducing the M2 
state, this suggests that additional signals are necessary for this transition. Pancreatic cancer 
cell conditioned media was capable of inducing the M2 phenotype in vitro, also indicating 
that there are additional soluble factors secreted by tumor cells that influence macrophage 
state in the microenvironment. Among these, one report implicated lactate as a mediator of 
the M1-M2 transition30. The resultant skew towards the M2 phenotype is associated with 
increased expression of Arginase-I. Interestingly, increased metabolism of L-arginine is 
associated with the accumulation of ornithine and proline, precursors of collagen 
synthesis31. Histologically, we observed that most MRC1+ macrophages were embedded in 
dense stromal compartments characterized by abundant collagen deposition. In contrast, 
classically activated MHCII+ macrophages were not surrounded by stroma and maintained a 
large phagocytic phenotype consistent with their role as antigen-presenting cells. These 
results raise the possibility that the accumulation of alternatively activated macrophages 
within the tumor may result in increased arginine metabolism and collagen deposition, 
potentially contributing to the profound desmoplasia observed in the pancreatic cancer 
microenvironment. Our findings are consistent with those recently reported in a study that 
dissected the relative contribution of tissue resident versus bone marrow derived 
macrophages to pancreatic tumor progression. In this study, it was the F4/80+MHClow 
subset of macrophages which were most often tissue derived, that were associated with 
tumor progression and fibrosis32. Consistent with this study, we found that F4/80+/MRC1+ 
macrophages frequently co-express Ki67, and therefore acquire and maintain the ability to 
proliferate alongside cancer cells. Our studies also suggest that Mst1r signaling in pancreatic 
cancer cells results in secretion of Ccl2, a ligand for the Ccr2 receptor. Ccl2 has been shown 
to mediate trafficking of bone marrow derived monocytes to the pancreatic tumor 
microenvironment and influence tumor progression and prognosis22,23. Our findings are also 
consistent with the findings of Gardner et al. who noted a correlation of Ccl2 in a liver injury 
model33.
These results provide evidence of a positive feedback autocrine and paracrine Mst1-Mst1r 
signaling axis, and thereby suggest that targeting the Mst1-Mst1r axis may not only have a 
direct effect on the tumor cell but may have the added benefit of therapeutic 
immunomodulation within the tumor microenvironment. In the rapidly evolving field of 
cancer immunotherapy, targeting activities of the tumor-associated macrophage has emerged 
as one central therapeutic arm of investigation. The two primary strategies have been; 1) to 
modulate the activation state of the macrophage, and 2) exclusion of the macrophage from 
the tumor microenvironment. Successful modulation of macrophage phenotypes will require 
a thorough understanding of the signals driving activation states. Our data suggests Mst1r 
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signaling may contribute to this modulation in the pancreatic cancer microenvironment and 
is therefore worthy of further study as an immunomodulatory strategy in this disease.
MATERIALS and METHODS
Mice
Animal protocols were approved by the UCSD Institutional Animal Care and Use 
Committee. PDX-1-cre, KrasLSLG12D and the Mst1r kinase deficient strain, (TK−/−) were 
described previously4,8. PDX-1-Mst1r animals were generated by insertion of a murine 
Mst1r mini-gene coding for wild type Mst1r protein under the control of the PDX-1 
promoter9. PDX-1-Mst1r mice were screened for their pancreatic expression of Mst1r by 
western blot (Supplemental 1A,B). Mice with 2-fold increase in Mst1r were propagated 
forward. All strains were C57BL/6J except for the KrasLSLG12D, (B6/129S4). All 
experiments used littermate control mice and equal numbers of each gender. C57BL/6J/
129S4 F1 hybrid mice were used for orthotopic implantation experiments. For animal 
studies group sizes were calculated by power analyses based on preliminary experiments 
using a significance level of 5% and a power of 80%. Animals were randomly assigned to 
experimental groups. The investigators were not blinded to allocation during experiments 
and outcome assessments. For genetically engineered mouse studies, equal numbers of male 
and female animals were used. Orthotopic experiments used male mice, aged 6–8 weeks.
Generating Epithelial Cell Lines
Pancreatic tissues were harvested from KrasCre (KC) and KrasRonCre (KRC) mice. Tissue 
fragments were embedded in Matrigel coated dishes and incubated at 37°C. Epithelial cells 
were isolated and propagated by clonal expansion. Mst1r knockdown and control lines were 
generated using shRNAs from Open Biosystems (Thermo Scientific) for mouse Mst1r, 
mouse Mst1 or scrambled control in the lenti pLKO.1 vector (Supplemental Table 1). Clones 
were isolated and analyzed for knockdown by Q-RT-PCR (Supplemental Table 2) and 
western blot (Anti-Mst1 Abcam, 1:3000 dilution).
Single Cell Suspensions
After sacrifice, intra-cardiac perfusion was performed with cold PBS. The body and tail of 
the pancreas were uniformly used for flow cytometry. The pancreatic head was placed in 
10% saline-buffered formalin and paraffin embedded for histology. The body and tail were 
minced into 1–2mm pieces in dissociation buffer. Single cell suspensions were incubated at 
37oC for 15 min and then passed through a 70uM filter into separation buffer containing 
EDTA. Cells were spun, counted and viability determined on a coulter counter.
Histology
Tissue sections were fixed overnight in 10% NBF and transferred to 70% ethanol. Paraffin 
embedding and cutting of tissue sections was performed by the UCSD Histology Core. 
Slides were baked overnight at 60°C and then either hematoxylin and eosin stained or 
processed for immunohistochemistry/immunofluorescence. Slides were cover-slipped with 
Permount (Fisher Scientific) and stored at room temperature. Antibodies/dilutions for are 
detailed in Supplemental Table 3.
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Flow Cytometry
Cell pellets were re-suspended in 0.5% BSA in PBS. 1×106 cells were stained with 
fluorochrome conjugated antibodies at 4°C for 30 minutes. Cells were rinsed with 2mL cold 
PBS and spun at 1500 rpm to pellet. Supernatant was removed and the cells were re-
suspended in 200uL of stabilizing fixative. Aqua Live/Dead Stain (Invitrogen) was used to 
exclude dead cells from the analysis. 2uL of BD Fc Block per tube was added and incubated 
at room temperature for 5 minutes prior to adding antibodies. Cells were analyzed on a 
Canto RUO Analyzer or FACS Aria Sorter equipped with 488 Argon, 633 Hene, and 405 
Violet Lasers. Analyses were performed using FlowJo software in consultation with the 
UCSD/VA Research Flow Cytometry Core.
Bone marrow derived macrophage experiments
Primary murine macrophages were generated by flushing the bone marrow from the femur 
and tibia of C57BL/6 mice, followed by incubation for 5 days in DMEM containing 10% 
FBS and 10 ng/mL murine M-CSF (Peprotech). BMMs were subsequently cultured in 
DMEM containing 2% serum in the presence or absence of murine recombinant M-CSF 
(Peprotech) for 24 hours. Macrophages were then stimulated for 24h with relevant ligands 
and then cells were lysed and RNA prepared using the RNAeasy Kit (Qiagen).
Quantitative RT-PCR (Q-RT-PCR)
RNA was extracted from pancreata using Trizol (Invitrogen) and quality checked by gel 
electrophoresis. Cell lines were plated to achieve 90% confluency. Treatment groups 
included DMEM Complete alone or DMEM Complete with 100ng/ml recombinant murine 
Mst1 (R&D 6244-MS). Cells were incubated for the indicated times or overnight, after 
which time RNA was isolated using Trizol, then treated with DNAase1 (Invitrogen).
cDNA was synthesized from 1 μg of RNA using iScript cDNA Synthesis Kit (BioRad). Q-
RT-PCR was performed using SoFast EvagGreen Supermix (BioRad) with cDNA 
corresponding to 50ng of total RNA and 500nM primers in a 20μl volume. Primers 
(sequences detailed in Supplemental Table 2) were examined by gel electrophoresis then 
sequenced. Relative fold change was calculated using the 2−ΔΔCt method with actin used to 
normalize. Either an untreated cell line, normal pancreas or KCE 329 cell line was used as 
the calibrator to generate the fold change10. Significance was set at 1.5-fold above or below 
the reference sample.
Orthotopic Experiments
6–8 month old F1 Hybrid male mice (B6129SF1/J mice, Jackson Laboratories, ME) were 
injected with 700,000 LMP cells into the pancreas using a 29G 1/2cc syringe. Tumors 
originating from the injection were allowed to grow for 3.5 weeks. Mice were then 
euthanized with the tumor removed and either fixed in 10% NBF, homogenized in Trizol 
(Life Technologies, CA) for RNA extraction or flash frozen in liquid Nitrogen and stored at 
−80oC for future processing.
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Gene expression analyses
The GSE71729 dataset was downloaded from the Gene Expression Omnibus (GEO; http://
www.ncbi.nlm.nih.gov/gds). The dataset corresponds to an Agilent human whole-genome 
4×44K microarray (Agilent Technologies) and contains gene expression profiling for 46 
normal pancreas specimens and 125 pancreatic cancers with matching clinical information. 
TCGA RNAseqV2 normalized expression values have been downloaded from the Genetic 
Data Commons Data Portal (https://portal.gdc.cancer.gov). 99 samples from the TCGA 
cohort with Mst1r expression values and clinical annotation were utilized for survival 
analysis. Selected samples show consistent OS time and status regarding clinical annotations 
retrieved from TCGA and Cbioportal websites (difference in median OS time <0.2 month). 
Survival curves and associated statistics were generated using GraphPad Prism. Patient 
stratification corresponding to high and low expression was performed using Cutoff Finder 
(http://molpath.charite.de/cutoff/). P-values refer to log-rank tests for survival curves and to 
unpaired t-test with Welch’s correction for boxplot.
Statistics
Data was analyzed using Student’s t test and ANOVA where appropriate. Survival analyses 
were performed using the Kaplan-Meier method. Flow cytometry data was analyzed using 
the nonparametric Kruskal-Wallis test. The Spearman’s rho coefficient was calculated for all 
correlations. All statistical tests were 2-sided, and p-values are reported where appropriate. 
Microsoft Excel, GraphPad Prism 5, and SPSS Statistical software were used for the 
analyses.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Mst1r Promotes Pancreatic Cancer Initiation and Progression
(A) Low grade PanIN in a 6m KC mouse (B) Expansive PanIN formation in 6m KRC 
mouse. (C) Immunofluorescent staining for amylase (red, acini) and CK19 (green, ductal 
epithelium), confirming ADM within lesions of KRC pancreata (arrows). (D) Representative 
section from 6m KRC pancreas demonstrating sporadic areas of increased Mst1r expression 
(red) that correlate with nuclear expression of Pdx-1 (green), indicating the presence of the 
Pdx-1-Mst1r transgene. (E) Representative sections of KC, KRC and KTK−/−C pancreata 
demonstrates that KRC develop earlier onset of high grade PanIN2 and 3 compared to KC 
controls and KTK−/−C pancreata. (F) KRC animals have decreased survival compared with 
KC controls. Median survival 47 weeks (95% confidence interval 43–51 weeks) KC 
littermates failed to reach median survival in this cohort, p=0.004. (G) KTK−/−C animals 
have increased survival compared with KC controls. Median survival 63 weeks in KTK−/−C 
animals vs. 53 weeks in KC animals p=0.02 (Log-rank (Mantel-Cox) test).
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Figure 2. Mst1r Effects Composition of the Immune Cell Infiltrate
(A) Representative immunofluorescent staining of 6m KC and KRC mice revealing an 
increased infiltrate of F4/80+ cells (red) in KRC pancreata. (B) Immunohistochemistry from 
6 week animals demonstrating the reduced F4/80+ cell infiltrate in KTK−/−C compared to 
KC pancreata. Quantitation revealed a significant reduction in F4/80 positive cells in KTK
−/−C pancreata p=0.01 (C) Fluorescence double labelling for CD68/CD163 demonstrates an 
increase in KRC versus KC and KTK−/−C pancreata at multiple timepoints. (D) The average 
number of CD68/CD163 double labelled cells from KC, KRC and KTK−/−C were 
quantitated revealing an increasing number of double labelled cells with functional Mst1r 
overexpression at multiple timepoints, and a relation to strain by 2way ANOVA, p<0.0001.
(E) Pancreatic tissues were analyzed with flow cytometry. KRC and KC pancreata 
demonstrated a comparable infiltrate of CD11b+ Gr1low cells. (F) 12m pancreata from KRC, 
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KC and KTK−/−C mice analyzed by flow cytometry. Note the predominance of CD45+ 
CD11b+ Gr1low CD11c− MRC1+ macrophages in KRC compared to the KC and KTK−/−C 
animals. The percentage of CD45+ CD11b+ Gr1low MRC1+ macrophages present in the 12m 
pancreata from the KRC, KC and
KTK−/−C animals analyzed by flow is represented (One-way ANOVA p=0.003). (G) 9m 
pancreata were analyzed for expression of Mst1r by qRT-PCR. Pancreata with high levels of 
Mst1r expression, regardless of strain, showed an increased percentage of CD45+ CD11b+ 
Gr1low CD11c+ MRC1+ cells compared to pancreatic tissues with low Mst1r expression 
(p=0.01). Data represents frequencies of gated cell populations, means were compared with 
non-parametric Kruskal-Wallis Test.
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Figure 3. Mst1r-Mst1r Signaling Attenuates M1 Differentiation, but does not Independently 
Drive M2 Differentiation In Vitro
Bone marrow derived myeloid cells were isolated and treated with either IL-4 or IFN-g to 
induce M1 or M2 macrophage polarization, respectively. Cells were treated with either 
Mst1, LMP conditioned media, or a combination of both Mst1 and LMP conditioned media. 
Cytokine expression was assayed by qRT-PCR (A) Mst1 attenuated M1 macrophage 
polarization, shown by decreased INFγ, IL-12b and iNOS. (B) Mst1 did not independently 
induce M2 polarization, as it failed to induce expression of Arginase-I or TGFβ. LMP-
conditioned media was capable of inducing M2 macrophage differentiation. Data reflect 
mean fold change +/− SEM.
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Figure 4. Mst1r Signaling Upregulates Mst1 Expression
(A) KRC and CK epithelial cell lines derived from KC and KRC pancreata were screened 
for their relative expression of Mst1r and Mst1 by qRT-PCR. High levels of Mst1r 
expression correlated with similarly high levels of Mst1 expression in 3 out of 4 KRC 
epithelial cell lines. (B&C) Luciferase reporter assay results from murine pancreatic cell 
lines PanIN 4313 and 4964 LM. Cells were stimulated with 250ng/ml of Mst1 for 24–48h. A 
regulatory response element was located between −335bp and −485bp within the Mst1r 
promoter (p<0.0001, p =0.002). (D) Bone marrow-derived macrophages were exposed to 
100 ng/mL Mst1 or vehicle. Q-RT-PCR demonstrated a significant increase in Mst1r 
transcript after Mst1 (p< 0.05). (E) Immunostaining in 9m pancreata demonstrate increased 
Mst1 expression in high grade PanIN lesions in KRC versus KC mice.
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Figure 5. Mst1/Mst1r Regulates Orthotopic Pancreatic Cancer Growth
(A) shRNA knockdown resulted in ~90% reduction in Mst1 expression in LMP cells 
compared to control. B) Mst1 KD tumors weighed significantly less than control tumors 
(p<0.001). (C) Flow cytometry was performed on single cell suspensions derived from LMP 
control or Mst1 knockdown tumors. Flow sorting demonstrated a reduction in MRC1+/
CD11b+Grl− cells derived from Mst1 knockdown tumors, p=0.03. (D) Immunostaining for 
CD3 in LMP and LMP Mst1 KD tumors reveal an increase in CD3+ cells in the LMP Mst1 
KD compared to the control LMP-derived tumors. (E) Multiplex ELISA assay of 
conditioned media from LMP control versus LMP Mst1 knockdown cell lines revealed an 8 
fold reduction in Ccl2. (F) Q-RT-PCR for Ccl2 in 3 and 6 month old KRC and KTK−/−C 
pancreata demonstrated greater than 2 fold reduction in expression in the absence of 
functional Mst1r kinase.
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Figure 6. Mst1r Activates a Feed-Forward Autocrine-Paracrine Signaling Loop that Effects 
Tumor Growth and Survival
(A) Model suggesting that Mst1r overexpression results in increased Mst1 and increased 
Ccl2 within the tumor microenvironment, contributing to the attenuation of M1 
differentiation and skewing macrophages towards an alternative tumor-promoting M2 state. 
(B&C) Analysis of the TCGA’s pancreatic cancer cohort revealed the association between 
high MST1R expression and both poor overall (p = 0.0009) and disease-free survival (p < 
0.0001).
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